Continuing a trend that began in June, the largest biopharma deals of 2020 have all occurred this summer, led by the $6.3 billion global partnership on cancer immune therapies between Tango Therapeutics Inc. and Gilead Sciences Inc. earlier this month. The second highest deal for the year, worth $6 billion, was signed in July for Astrazeneca plc to develop and commercialize Daiichi Sankyo Co. Ltd.s DS-1062 everywhere but Japan for lung and breast cancers.
Biopharma deals and M&As tracked by BioWorld are updated and can be found in BioWorld Snapshots. So far, 2020 has recorded 1,324 deals valued at $129 billion, an amount that is nearing the 1,608 and $160 billion for all of 2019. In contrast, the mergers and acquisitions activity has been a bit lackluster, with 79 M&As valued at $121.4 billion vs. 173 valued at $224 billion in 2019. Nine of the top 10 M&As for this year occurred in the first half of 2020. The tenth highest is Alexion Pharmaceuticals Inc.’s $1.4 billion acquisition of Portola Pharmaceuticals Inc. in July.
Of the 308 licensing, collaborations and joint ventures completed in July and August, 21%, or a total of 65, were focused on COVID-19 therapeutics and vaccines.